<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432835</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0185</org_study_id>
    <nct_id>NCT00432835</nct_id>
  </id_info>
  <brief_title>Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis</brief_title>
  <official_title>Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine if temporary gastric electrical stimulation will
      help improve symptoms of gastroparesis (abnormal stomach emptying). We hypothesize that when
      the device is ON, Gastrointestinal symptoms will decrease by at least 50% from baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric Electrical Stimulation is an established treatment for drug-refractory patients who
      have the symptoms of gastroparesis/gastropathy. The symptoms of GP are nausea, vomiting,
      anorexia/early satiety, bloating/distention and abdominal pain and are classically associated
      with delayed gastric emptying of solids. The technique of GES was first used, in a patient
      seen at University of Tennesse-Memphis in 1993 and has undergone several clinical trials,
      particularly the GEMS trial, a feasibility trial starting in 1995 and the WAVESS trial, a
      double-blind trial begun in 1997. Both were international trials, showing promising results,
      and both have been published in the last 2 years. However, a number of issues related to who
      would benefit the most from Gastric Electrical Stimulation therapy have emerged. Among these
      issues are whether patients with etiologies other than diabetic or idiopathic gastroparesis,
      such as post-surgical gastropathy, which is often related to rapid, not delayed gastric
      emptying could be helped.

      Most recently a technique for the temporary placement of a Gastric Electrical Stimulation
      electrode in the stomach with an upper endoscope, combined with an external Gastric
      Electrical Stimulation device, has been tried and validated, first at UAMS in Little Rock,
      AR, beginning in 2001 and more recently here at UMMC, beginning later in 2001 and up until
      the present time. Using the technique of temporary gastric electrical stimulation, we have
      been able to demonstrate that TempStim can quickly demonstrate (in a manner of days) that a
      patient will respond to temporary GES, as quantified by a decrease in GI total symptoms and
      an improvement and normalization in solid gastric emptying.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom of Vomiting Associated With Gastroparesis</measure>
    <time_frame>Study Day 0 (Baseline), Day 3, Day 7</time_frame>
    <description>Likert Scale 0-4 (low-high) using a patient reported outcomes tool</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom of Nausea Associated With Gastroparesis</measure>
    <time_frame>Study Day 0 (Baseline), Day 3, Day 7</time_frame>
    <description>Likert Scale 0-4 (low-high) using a patient reported outcomes tool</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom of Gastric Emptying Time (GET) Associated With Gastroparesis</measure>
    <time_frame>Study Day 0 (Baseline), Day 4, Day 8</time_frame>
    <description>Transit time of a radio-labeled meal through the stomach, measured by scintigraphy for %contents remaining in the stomach at 1 hour, 2 hours, and 4 hours. GET measures were obtained at baseline, during the period allowed for 'washout', and on the final study day.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Gastric Stimulation Days1-4/Sham5-8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham1-4/Gastric Stimulation Days5-8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gastric Electrical Stimulator, Enterra, Medtronics, Inc.</intervention_name>
    <description>All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation</description>
    <arm_group_label>Gastric Stimulation Days1-4/Sham5-8</arm_group_label>
    <arm_group_label>Sham1-4/Gastric Stimulation Days5-8</arm_group_label>
    <other_name>No other name currently exists.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sex: Male of Female

          -  Age Range: 18 to 70 inclusive

          -  Patients with GP of diabetic, surgically related or idiopathic etiology.

          -  Symptoms of GP for &gt;/= 1 year.

          -  Refractory or intolerant to antiemetic drug classes (antihistamines and
             phenothiazines, serotonin receptor antagonists, dopamine receptor antagonists)

          -  Chronic vomiting and/or nausea with 7 or more episodes per week for either symptom
             irrespective of GET values.

          -  The patient is willing and able to provide informed consent.

          -  The patient is willing and able to return for required follow-up visits.

        Exclusion Criteria:

          -  Patients &lt; 18 or &gt;70 years in age.

          -  Patients with an active infection of any kind.

          -  Patients who the investigator determines are not candidates for endoscopic procedures.

          -  Women who are pregnant

          -  Inability or unwillingness to provide informed consent

          -  Unwilling or unable to return for required follow-up visits and examinations.

          -  Patients who are currently enrolled in another investigation of a medical device or
             drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas L Abell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gastrointestinal+endoscopy%22%5BJour%5D+AND+74%5Bvolume%5D+AND+3%5Bissue%5D+AND+496%5Bpage%5D+AND+2011%5Bpdat%5D+AND+Abell%5Bfirst+author%5D+AND+double-masked&amp;TransSchema=title&amp;cmd=detailssearch</url>
    <description>Pub Med abstract of study as reported in &quot;Gastrointestinal Endoscopy&quot;</description>
  </link>
  <results_reference>
    <citation>Abell TL, Johnson WD, Kedar A, Runnels JM, Thompson J, Weeks ES, Minocha A, Griswold ME. A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. Gastrointest Endosc. 2011 Sep;74(3):496-503.e3. doi: 10.1016/j.gie.2011.05.022.</citation>
    <PMID>21872708</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2007</study_first_submitted>
  <study_first_submitted_qc>February 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2007</study_first_posted>
  <results_first_submitted>April 11, 2012</results_first_submitted>
  <results_first_submitted_qc>November 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2012</results_first_posted>
  <last_update_submitted>November 1, 2012</last_update_submitted>
  <last_update_submitted_qc>November 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Thomas Abell, MD</investigator_full_name>
    <investigator_title>Principal Investigator, Professor of Medicine, Director, Division of Digestive Diseases</investigator_title>
  </responsible_party>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <keyword>Delayed gastric emptying</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Post-Surgical</keyword>
  <keyword>Idiopathic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients seeking temporary gastric electric stimulator devices for drug-refractory gastroparesis between August 2005 and October 2006 who met the inclusion criteria and did not have any of the exclusion criteria were offered access to the research protocol.</recruitment_details>
      <pre_assignment_details>No significant events or approaches for the overall study following participant enrollment were performed prior to group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gastric Stimactivated Days1-4/Not Activated Days5-8</title>
          <description>The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal Electrogastrogram, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days</description>
        </group>
        <group group_id="P2">
          <title>Gastric StimulationNotActivated Days1-4/Activated Days5-8</title>
          <description>The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 1st Intervention</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 2nd Intervention</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22">These 22 patients completed the entire 8 day protocol.</participants>
                <participants group_id="P2" count="23">These 23 patients completed the entire 8 day protocol.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse event: lead dislodgement.</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gastric Stimactivated Days1-4/Not Activated Days5-8</title>
          <description>The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal Electrogastrogram, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days</description>
        </group>
        <group group_id="B2">
          <title>Gastric StimulationNotActivated Days1-4/Activated Days5-8</title>
          <description>The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="13"/>
                    <measurement group_id="B2" value="47" spread="14"/>
                    <measurement group_id="B3" value="47" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Symptom of Vomiting Associated With Gastroparesis</title>
        <description>Likert Scale 0-4 (low-high) using a patient reported outcomes tool</description>
        <time_frame>Study Day 0 (Baseline), Day 3, Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gastric Stimactivated Days1-4/Not Activated Days5-8</title>
            <description>The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal Electrogastrogram, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days</description>
          </group>
          <group group_id="O2">
            <title>Gastric StimulationNotActivated Days1-4/Activated Days5-8</title>
            <description>The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal electrogastrogram, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom of Vomiting Associated With Gastroparesis</title>
          <description>Likert Scale 0-4 (low-high) using a patient reported outcomes tool</description>
          <units>Patient Self-reported Symptom Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vomiting Score Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="1.55"/>
                    <measurement group_id="O2" value="2.68" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Score Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.67"/>
                    <measurement group_id="O2" value="1.20" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting Score Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="1.44"/>
                    <measurement group_id="O2" value="0.72" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Symptom of Nausea Associated With Gastroparesis</title>
        <description>Likert Scale 0-4 (low-high) using a patient reported outcomes tool</description>
        <time_frame>Study Day 0 (Baseline), Day 3, Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gastric Stimactivated Days1-4/Not Activated Days5-8</title>
            <description>The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal Electrogastrogram, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days</description>
          </group>
          <group group_id="O2">
            <title>Gastric StimulationNotActivated Days1-4/Activated Days5-8</title>
            <description>The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal electrogastrogram, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom of Nausea Associated With Gastroparesis</title>
          <description>Likert Scale 0-4 (low-high) using a patient reported outcomes tool</description>
          <units>Patient Self-reported Symptom Score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nause Score Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="0.92"/>
                    <measurement group_id="O2" value="3.33" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea Score Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="1.29"/>
                    <measurement group_id="O2" value="1.67" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea Score Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="1.18"/>
                    <measurement group_id="O2" value="1.4" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Symptom of Gastric Emptying Time (GET) Associated With Gastroparesis</title>
        <description>Transit time of a radio-labeled meal through the stomach, measured by scintigraphy for %contents remaining in the stomach at 1 hour, 2 hours, and 4 hours. GET measures were obtained at baseline, during the period allowed for 'washout', and on the final study day.</description>
        <time_frame>Study Day 0 (Baseline), Day 4, Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gastric Stimactivated Days1-4/Not Activated Days5-8</title>
            <description>The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal Electrogastrogram, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days</description>
          </group>
          <group group_id="O2">
            <title>Gastric StimulationNotActivated Days1-4/Activated Days5-8</title>
            <description>The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal electrogastrogram, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom of Gastric Emptying Time (GET) Associated With Gastroparesis</title>
          <description>Transit time of a radio-labeled meal through the stomach, measured by scintigraphy for %contents remaining in the stomach at 1 hour, 2 hours, and 4 hours. GET measures were obtained at baseline, during the period allowed for 'washout', and on the final study day.</description>
          <units>percentage of radiolabeled meal in stoma</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GET Day 0, at 1st hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.07" spread="20.23"/>
                    <measurement group_id="O2" value="66.13" spread="25.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GET Day 0, at 2nd hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.96" spread="23.79"/>
                    <measurement group_id="O2" value="37.41" spread="28.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GET Day 0, at 4th hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.71" spread="21.10"/>
                    <measurement group_id="O2" value="16.43" spread="23.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GET Day 4, at 1st hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.96" spread="23.79"/>
                    <measurement group_id="O2" value="62.35" spread="24.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GET Day 4, at 2nd hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.85" spread="25.30"/>
                    <measurement group_id="O2" value="38.00" spread="24.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GET Day 4, at 4th hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.11" spread="23.76"/>
                    <measurement group_id="O2" value="21.85" spread="28.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GET Day 8, at 1st hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.71" spread="21.10"/>
                    <measurement group_id="O2" value="68.67" spread="19.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GET Day 8, at 2nd hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.19" spread="24.37"/>
                    <measurement group_id="O2" value="40.92" spread="26.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GET Day 8, at 4th hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.71" spread="27.94"/>
                    <measurement group_id="O2" value="20.25" spread="25.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study Days 0-8 (Entirety of Study)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gastric Stimactivated</title>
          <description>Gastric Electrical Stimulation</description>
        </group>
        <group group_id="E2">
          <title>Gastric StimulationNotActivated</title>
          <description>Sham stimulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Lead Dislodgment</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lead Dislodgment</sub_title>
                <description>All lead dislodgment occurred by Day 4.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>New lead implantation techniques now minimize dislodgment (only adverse effect); Parallel, non-crossover protocol will address any carry-over effect after tGES activation OFF; stratification for baseline mucosal EGG and medications may be useful.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas L. Abell, MD, Professor of Medicine</name_or_title>
      <organization>University of Mississippi Medical Center</organization>
      <phone>6019844540</phone>
      <email>tabell@umc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

